Venture builder NeoSci Ventures raises S$70 million for inaugural biotech fund
Tuesday, November 3, 2026 · first reported by The Business Times and 1 other
NeoSci Ventures (NSV), a biotech investor based in Singapore, Taiwan and the US, has held a first close of its debut institutional venture fund at S$70 million, per The Business Times. Dealroom gives the figure as $54.7 million. The fund plans to back up to 12 biotech companies worldwide, and has already invested in two.
Limited partners include EDBI, Taiwan's National Development Fund, Catcher Technology and Crescendas Group, plus family offices and entrepreneurs. NSV may take founder, board or executive roles in portfolio companies early on. Target areas include oncology, autoimmune diseases and metabolic diseases.
- Firm
- NeoSci Ventures
- Also named
- EDBI, National Development Fund
- Fund
- NeoSci Ventures inaugural institutional venture fund
- Size
- $54.7M
- Stage
- First close
- Asset class
- Venture
- Geography
- Asia-Pacific, North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
Coverage
2 sources- Savory closes $201.5 million fund as startups in AI, healthcare and defense raise capitalUtah Business
- Yvonne Bajela is bringing $17M in fresh capital to Europe’s startup sceneTechCrunch +4
- VC Firm NSV Raises Nearly $55 Million in First Close of Inaugural Biotech FundWSJ
- “I didn't become a VC to be important. I became one to be useful”: Robin Capital raises €15M Fund IItech.eu +2
- Spotify, Lovable backer Creandum said to raise $750M new fundTradingView +1
- Seaya raises €600m at first close for €1bn European growth fund, opens London officeAltAssets
Got news? Send it to us →